Home » Stocks » CSTL

Castle Biosciences, Inc. (CSTL)

Stock Price: $56.24 USD -6.02 (-9.67%)
Updated May 6, 2021 4:00 PM EDT - Market closed
After-hours: $57.00 +0.76 (1.35%) May 6, 4:53 PM
Market Cap 1.56B
Revenue (ttm) 62.65M
Net Income (ttm) -10.28M
Shares Out 25.06M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $56.24
Previous Close $62.26
Change ($) -6.02
Change (%) -9.67%
Day's Open 61.38
Day's Range 55.80 - 61.67
Day's Volume 348,026
52-Week Range 29.00 - 107.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Melanoma--Castle Collaborates with the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S.

2 days ago - Business Wire

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 days ago - Zacks Investment Research

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AmericanAcademyofDermatology--Castle today announced its national sponsorship of the American Academy of Dermatology's (AAD) "Skin Cancer, Take a Hike!"

6 days ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DiffDxMelanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer tre...

1 week ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release its financial results for the first quarter 2021 and provide a pipeline update, after the close of market on May 10,...

1 week ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AADVMX2021--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatme...

1 week ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DNANurses--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatmen...

2 weeks ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #10thWCM--Castle presented data on its three skin cancer gene expression profile tests at the 10th World Congress of Melanoma.

2 weeks ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle presented new data on the integration of the DecisionDx®-Melanoma test with clinicopathologic features (i31-GEP).

3 weeks ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer ...

3 weeks ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Melanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment...

3 weeks ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announced it will collaborate with the Melanoma Research Foundation (MRF) to present “Ask the Expert” Managing Melanoma, a webina...

1 month ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer ...

1 month ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer...

1 month ago - Business Wire

The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days. We believe the st...

1 month ago - Forbes

Castle Biosciences, Inc. (CSTL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri...

1 month ago - Zacks Investment Research

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -45.45% and 10.62%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the st...

1 month ago - Zacks Investment Research

Shares of Castle Biosciences (NASDAQ:CSTL) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 254.55% year over year to ($0.17), whic...

1 month ago - Benzinga

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences Announces Fourth Quarter and Full-Year 2020 Results

1 month ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences Launches DecisionDx-Melanoma Integrated Test Result Utilizing Artificial Intelligence to Predict Individualized Risk

1 month ago - Business Wire

Castle Biosciences (CSTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 months ago - Zacks Investment Research

Castle Biosciences, Inc. (CSTL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #SkinCancer--Castle will release its financial results for the fourth quarter and year-ended December 31, 2020, after the close of market on Monday, March 8...

2 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences is scheduled to present a company overview at upcoming investor conferences.

2 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle today announced virtual posters on its three skin cancer gene expression profile tests at the 19th Annual South Beach Symposium.

3 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Con...

3 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Castle--Castle today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2020.

3 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle is scheduled to present a company overview at the 23rd Annual Needham Virtual Growth Conference on Jan. 15, 2021.

4 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #skincancer--Castle today announced it prepaid in full its outstanding term loan facility.

4 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences today announced the closing of its previously announced underwritten public offering.

4 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences announced today the pricing of its underwritten public offering.

4 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle announced today that it has commenced a proposed underwritten public offering.

4 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma

5 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #cancerdiagnostics--Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference

5 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx® DiffDx™-Melanoma for Suspicious Pigment...

5 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDP2020--Castle today announced the presentation of data on two of its skin cancer gene expression profile tests during the 57th Meeting of ASDP.

5 months ago - Business Wire

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Catalyst Biosciences (CBIO), UFP Industries (UFPI), VeriSign (VRSN), InMode (INMD) and Castle Bi...

Other stocks mentioned: CBIO, INMD, UFPI, VRSN
5 months ago - Zacks Investment Research

Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #earnings--Castle today announced its financial results for the third quarter and nine months ended Sept. 30, 2020.

5 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle's president and CEO will present a company overview at the Canaccord Genuity 2020 Virtual MedTech & Diagnostics Forum on Nov. 19, 2020

6 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #GeneExpressionProfile--Castle Biosciences announced that DecisionDx® DiffDx™-Melanoma is now commercially available.

6 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDP--Castle will deliver two poster presentations at The ASDP 57th Virtual Annual Meeting.

6 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release its financial results for the third quarter ended Sept. 30, 2020, after the close of market on Monday, Nov. 9, 2020.

6 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle today announced that it will host an investor webcast to highlight the planned launch of the ConfirmDx®-Melanoma test.

6 months ago - Business Wire

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: DQ, HRI, SURF
6 months ago - Zacks Investment Research

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences Presents Data on DecisionDx-Melanoma at the Virtual European Association of Dermato-Oncology (EADO) Congress.

6 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDS--Castle announced its data were featured in two oral presentations during the 2020 ASDS Virtual Annual Meeting, Oct. 9-11, 2020.

6 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announced that Palmetto GBA MolDx has issued a final expanded local coverage determination for the company's DecisionDx®-Melanoma...

6 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDS--Castle announced its data will be featured in oral presentations during the 2020 American Society for Dermatologic Surgery Virtual Annual Meeting.

7 months ago - Business Wire

Castle Biosciences, Inc.'s (CSTL) CEO Derek Maetzold on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

About CSTL

Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, ... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jul 25, 2019
Stock Exchange
NASDAQ
Ticker Symbol
CSTL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price forecast is 87.17, which is an increase of 55.00% from the latest price.

Price Target
$87.17
(55.00% upside)
Analyst Consensus: Strong Buy